Skip to main content

Klass Russell Kevin's Form 4 filing

Zomedica Corp. (ZOMDF) · filed Jun 12, 2024

Accession no.
0001654954-24-007663
Filed
Jun 12, 2024, 4:15 PM ET
Trade date
Jun 10-11, 2024
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions. Open-market purchases total $105.0K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Klass Russell KevinCIK 0001999774Officer (Vice President of Sales)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 10, 2024Common Stock, without par valuePPurchaseAcquired+200,007$0.1497F1+$29,941.051,200,057Direct
Jun 11, 2024Common Stock, without par valuePPurchaseAcquired+500,000$0.1502F2+$75,1001,700,057Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported is the weighted average price. These shares were sold in multiple transactions ranging from $0.1495 to $0.1499, inclusive. The reporting person undertakes to provide to Zomedica Corp., any security holder of Zomedica Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the preceding sentence.

Referenced by the price of 1 transaction in Table I.

F2

The price reported is the weighted average price. These shares were sold in multiple transactions ranging from $0.1485 to $0.1526, inclusive. The reporting person undertakes to provide to Zomedica Corp., any security holder of Zomedica Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the preceding sentence.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)